{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:04:59Z","timestamp":1790222699499,"version":"4.1.0"},"reference-count":64,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["003341121"],"award-info":[{"award-number":["003341121"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["RC20230503228\/1\/1\/240"],"award-info":[{"award-number":["RC20230503228\/1\/1\/240"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators, such as elexacaftor\/tezacaftor\/ivacaftor (ETI), herald a new era in therapeutic strategy of cystic fibrosis (CF). ETI\u2019s effect on glucose tolerance remains controversial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The study was undertaken to evaluate the effect of ETI treatment on glucose tolerance in youths with CF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All the participants underwent a baseline oral glucose tolerance test (OGTT) before ETI initiation (M0) and 12 months (M12), and at 24 months if possible. The cohort was stratified in two subgroups based on the baseline OGTT: normal glucose tolerance (NGT) and abnormal glucose tolerance (AGT) defined by impaired fasting glucose or impaired glucose tolerance or diabetes not requiring insulin treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 106 adolescents with CF (age 14.1 \u00b1 1.5 years), 75 with NGT, and 31 with AGT. The baseline characteristics of the two groups were similar except for a higher glucose level at 1- and 2-hour OGTT in the AGT group. ETI induced an increase in body mass index z score and in forced expiratory volume in 1 second (FEV1) (P &amp;lt; .001). After 12 months, participants with NGT did not experience any change of 1-hour and 2-hour glucose. By contrast, those with AGT displayed a reduction of 2-hour glucose at M12 (P = .006). Fifteen out of the 31 (48%) adolescents in the AGT group reversed to NGT but 9 of 75 (17%) in the NGT group progressed to AGT. Three participants with CF-related diabetes at baseline reversed to AGT. One-hour glucose concentrations at or above 8.7 mmol\/L (157\u2005mg\/dL) during baseline OGTT had 80% sensitivity to identify those with AGT at 12 months (odds ratio 1.51; [1.20-1.92]; P = .001). Twenty participants had a 24-month OGTT that confirmed preserved insulin secretion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>ETI may improve glucose tolerance in adolescents with CF by preserving insulin secretion. One-hour glucose during the OGTT helps to detect risk for AGT after ETI treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf099","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:02:41Z","timestamp":1740052961000},"page":"3220-3229","source":"Crossref","is-referenced-by-count":9,"title":["Effect of Elexacaftor\/Tezacaftor\/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8885-3056","authenticated-orcid":false,"given":"Alfonso","family":"Galderisi","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Yale University , New Haven, CT 06510 ,","place":["USA"]},{"name":"H\u00f4pital Universitaire Necker-Enfants Malades\u2013APHP, Centre de R\u00e9f\u00e9rences Maladies Rares, Mucoviscidose et Maladies apparent\u00e9e , 75015 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1728-915X","authenticated-orcid":false,"given":"Laurence","family":"Weiss","sequence":"additional","affiliation":[{"name":"H\u00f4pitaux universitaires de Strasbourg-H\u00f4pital de Hautepierre, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose P\u00e9diatrique , 67200 Strasbourg ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Besan\u00e7on","sequence":"additional","affiliation":[{"name":"H\u00f4pital Universitaire Necker-Enfants Malades\u2013APHP, Centre de R\u00e9f\u00e9rences Maladies Rares, Mucoviscidose et Maladies apparent\u00e9e , 75015 Paris ,","place":["France"]},{"name":"H\u00f4pital Universitaire Necker-Enfants Malades\u2013APHP, Service d\u2019endocrinologie p\u00e9diatrique , 75015 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8884-0772","authenticated-orcid":false,"given":"Nathalie","family":"Stremler","sequence":"additional","affiliation":[{"name":"H\u00f4pital d'enfants de la Timone-Assistance Publique H\u00f4pitaux de Marseille, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose P\u00e9diatrique , 13005 Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2711-8319","authenticated-orcid":false,"given":"Philippe","family":"Reix","sequence":"additional","affiliation":[{"name":"H\u00f4pital Femme M\u00e8re Enfant-Hospices civils de Lyon, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose P\u00e9diatrique , 69677 Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Wizla","sequence":"additional","affiliation":[{"name":"H\u00f4pital Jeanne de Flandre-CHU de Lille, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose P\u00e9diatrique , 59037 Lilles ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Lustre","sequence":"additional","affiliation":[{"name":"H\u00f4pital Universitaire Necker-Enfants Malades\u2013APHP, Centre de R\u00e9f\u00e9rences Maladies Rares, Mucoviscidose et Maladies apparent\u00e9e , 75015 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinthia","family":"Rames","sequence":"additional","affiliation":[{"name":"CHU Amiens Picardie, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose , 80054 Amiens ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Tatopoulos","sequence":"additional","affiliation":[{"name":"H\u00f4pital d\u2019enfants de Nancy-CHRU Nancy, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose P\u00e9diatrique , 54511 Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6606-0821","authenticated-orcid":false,"given":"Caroline","family":"Perisson","sequence":"additional","affiliation":[{"name":"CHU La R\u00e9union, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose P\u00e9diatrique , 97448 Saint Pierre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6429-818X","authenticated-orcid":false,"given":"Marie-Laure","family":"Dalphin","sequence":"additional","affiliation":[{"name":"Centre hospitalier Jean Minjoz CHRU de Besan\u00e7on, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose P\u00e9diatrique , 25030 Besan\u00e7on ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Troussier","sequence":"additional","affiliation":[{"name":"CHU d\u2019Angers, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose , 49933 Angers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0119-2628","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Houdouin","sequence":"additional","affiliation":[{"name":"H\u00f4pital Robert-Debr\u00e9 APHP, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose P\u00e9diatrique , 75019 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7965-5418","authenticated-orcid":false,"given":"Katia","family":"Bessaci","sequence":"additional","affiliation":[{"name":"American Memorial Hospital CHU de Reims, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose Mixte , 51092 Reims ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9469-9796","authenticated-orcid":false,"given":"Laure","family":"Cosson","sequence":"additional","affiliation":[{"name":"H\u00f4pital de Clocheville-CHRU de Tours, Centre de r\u00e9f\u00e9rence de la mucoviscidose , 37044 Tours ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8396-7678","authenticated-orcid":false,"given":"Asma","family":"Gabsi","sequence":"additional","affiliation":[{"name":"H\u00f4pital Andr\u00e9 Mignot-Centre hospitalier de Versailles, Centre de r\u00e9f\u00e9rence de la mucoviscidose , 78150 Versaille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7026-7523","authenticated-orcid":false,"given":"Harriet","family":"Corvol","sequence":"additional","affiliation":[{"name":"H\u00f4pital Trousseau-APHP, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose P\u00e9diatrique , 75012 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4369-0000","authenticated-orcid":false,"given":"Eric","family":"Deneuville","sequence":"additional","affiliation":[{"name":"CHU de Rennes, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose P\u00e9diatrique , 35203 Rennes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Storni","sequence":"additional","affiliation":[{"name":"CH de Vannes-Lorient, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose P\u00e9diatrique , 70555 Vannes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9195-2183","authenticated-orcid":false,"given":"Sophie","family":"Ramel","sequence":"additional","affiliation":[{"name":"Fondation Ildys-CH de Roscoff, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose P\u00e9diatrique , 35033 Roscoff ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Bui","sequence":"additional","affiliation":[{"name":"Groupe hospitalier Pellegrin-CHU de Bordeaux, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose P\u00e9diatrique , 33076 Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Heraud","sequence":"additional","affiliation":[{"name":"CHU Estaing-Clermont-Ferrand, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose P\u00e9diatrique , 63003 Clermont-Ferrand ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4849-9034","authenticated-orcid":false,"given":"Natascha","family":"Remus","sequence":"additional","affiliation":[{"name":"Centre hospitalier intercommunal de Cr\u00e9teil, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose , 94010 Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0252-1264","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Huet","sequence":"additional","affiliation":[{"name":"CHU Dijon Bourgogne, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose , 21070 Dijon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuella","family":"Scalbert","sequence":"additional","affiliation":[{"name":"Centre hospitalier de Dunkerque, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose , 59385 Dunkerque ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3790-085X","authenticated-orcid":false,"given":"Laurent","family":"Mely","sequence":"additional","affiliation":[{"name":"H\u00f4pital Ren\u00e9e Sabran-Hospices civils de Lyon, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose , 83400 Giens ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Gachelin","sequence":"additional","affiliation":[{"name":"CHU F\u00e9lix-Guyon La R\u00e9union, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose P\u00e9diatrique , 97405 Saint Denis La R\u00e9union ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Giannantonio","sequence":"additional","affiliation":[{"name":"H\u00f4pitaux P\u00e9diatriques de Nice CHU Lenval, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose , 51069 Nice ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6679-5772","authenticated-orcid":false,"given":"Alexia","family":"Letierce","sequence":"additional","affiliation":[{"name":"H\u00f4pital Universitaire Necker-Enfants Malades\u2013APHP, Centre de R\u00e9f\u00e9rences Maladies Rares, Mucoviscidose et Maladies apparent\u00e9e , 75015 Paris ,","place":["France"]},{"name":"QualityStat , 91420 Morangis ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djouher","family":"Sahki","sequence":"additional","affiliation":[{"name":"H\u00f4pital Universitaire Necker-Enfants Malades\u2013APHP, Centre de R\u00e9f\u00e9rences Maladies Rares, Mucoviscidose et Maladies apparent\u00e9e , 75015 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1545-1184","authenticated-orcid":false,"given":"Christophe","family":"Marguet","sequence":"additional","affiliation":[{"name":"CHU de Rouen, Centre de Ressources et de Comp\u00e9tence de la Mucoviscidose , 76031 Rouen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Bonnel","sequence":"additional","affiliation":[{"name":"H\u00f4pital Universitaire Necker-Enfants Malades\u2013APHP, Centre de R\u00e9f\u00e9rences Maladies Rares, Mucoviscidose et Maladies apparent\u00e9e , 75015 Paris ,","place":["France"]},{"name":"H\u00f4pital Andr\u00e9 Mignot-Centre hospitalier de Versailles, Centre de r\u00e9f\u00e9rence de la mucoviscidose , 78150 Versaille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5537-9482","authenticated-orcid":false,"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[{"name":"H\u00f4pital Universitaire Necker-Enfants Malades\u2013APHP, Centre de R\u00e9f\u00e9rences Maladies Rares, Mucoviscidose et Maladies apparent\u00e9e , 75015 Paris ,","place":["France"]},{"name":"INSERM U1151, Institut Necker Enfants Malades , 75015 Paris ,","place":["France"]},{"name":"European Respiratory Network Lung , 60596 Frankfurt ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"issue":"5","key":"2025101519574038000_dgaf099-B1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2025101519574038000_dgaf099-B2","first-page":"192","article-title":"Elexacaftor-tezacaftor-ivacaftor: the first triple-combination cystic fibrosis transmembrane conductance regulator modulating therapy","volume":"25","author":"Ridley","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"16","key":"2025101519574038000_dgaf099-B3","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.3390\/ijms21165882","article-title":"From ivacaftor to triple combination: a systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis","volume":"21","author":"Gramegna","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"19","key":"2025101519574038000_dgaf099-B4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"2025101519574038000_dgaf099-B5","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2025101519574038000_dgaf099-B6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"10212","key":"2025101519574038000_dgaf099-B7","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"3-4","key":"2025101519574038000_dgaf099-B8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/17476348.2024.2357210","article-title":"Unmet challenges in cystic fibrosis treatment with modulators","volume":"18","author":"Corrao","year":"2024","journal-title":"Expert Rev Respir Med"},{"issue":"3","key":"2025101519574038000_dgaf099-B9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3390\/diagnostics11030572","article-title":"Cystic fibrosis-related diabetes (CFRD): overview of associated genetic factors","volume":"11","author":"Iafusco","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"2025101519574038000_dgaf099-B10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1164\/rccm.201806-1018OC","article-title":"Islet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy","volume":"199","author":"Kelly","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2025101519574038000_dgaf099-B11","first-page":"100287","article-title":"The role of genetic modifiers, inflammation and CFTR in the pathogenesis of cystic fibrosis related diabetes","volume":"27","author":"Hasan","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"6","key":"2025101519574038000_dgaf099-B12","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/clinem\/dgac020","article-title":"New concepts in the pathogenesis of cystic fibrosis-related diabetes","volume":"107","author":"Moheet","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025101519574038000_dgaf099-B13","doi-asserted-by":"crossref","first-page":"e1670","DOI":"10.1210\/clinem\/dgae474","article-title":"A longitudinal study of glucose tolerance in cystic fibrosis: the central role of beta cell functional mass","volume":"110","author":"Piona","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2025101519574038000_dgaf099-B14","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.2147\/JIR.S365772","article-title":"An inflammatory signature of glucose impairment in cystic fibrosis","volume":"15","author":"Montemari","year":"2022","journal-title":"J Inflamm Res"},{"issue":"2","key":"2025101519574038000_dgaf099-B15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"2025101519574038000_dgaf099-B16","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/ppul.26388","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on body composition in a small cohort of youth with cystic fibrosis","volume":"58","author":"Granados","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"2025101519574038000_dgaf099-B17","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jcf.2023.01.004","article-title":"Improved glucose tolerance after initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis","volume":"22","author":"Steinack","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"6","key":"2025101519574038000_dgaf099-B18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jcf.2018.03.008","article-title":"Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline","volume":"17","author":"Chan","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"7","key":"2025101519574038000_dgaf099-B19","first-page":"e41697","article-title":"The effects of elexacaftor, tezacaftor, and ivacaftor (ETI) on blood glucose in patients with cystic fibrosis: a systematic review","volume":"15","author":"Salazar-Barragan","year":"2023","journal-title":"Cureus"},{"key":"2025101519574038000_dgaf099-B20","doi-asserted-by":"crossref","first-page":"107664","DOI":"10.1016\/j.rmed.2024.107664","article-title":"Long-term therapy with CFTR modulators consistently improves glucose metabolism in adolescents and adults with cystic fibrosis","volume":"228","author":"Cohen","year":"2024","journal-title":"Respir Med"},{"issue":"1","key":"2025101519574038000_dgaf099-B21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcf.2023.11.005","article-title":"Decline in HbA1c during the first year of elexacaftor\/tezacaftor\/ivacaftor treatment in the Danish cystic fibrosis cohort: short title: decline in HbA1c after elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"23","author":"Nielsen","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2025101519574038000_dgaf099-B22","first-page":"100320","article-title":"Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes","volume":"33","author":"Lurquin","year":"2023","journal-title":"J Clin Transl Endocrinol"},{"issue":"8","key":"2025101519574038000_dgaf099-B23","doi-asserted-by":"crossref","first-page":"e98240","DOI":"10.1172\/jci.insight.98240","article-title":"Cystic fibrosis-related diabetes is caused by islet loss and inflammation","volume":"3","author":"Hart","year":"2018","journal-title":"JCI insight"},{"key":"2025101519574038000_dgaf099-B24","first-page":"100307","article-title":"CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy","volume":"30","author":"Crow","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"2","key":"2025101519574038000_dgaf099-B25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"2025101519574038000_dgaf099-B26","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"239","key":"2025101519574038000_dgaf099-B27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/adc.45.239.13","article-title":"Variations in the pattern of pubertal changes in boys","volume":"45","author":"Marshall","year":"1970","journal-title":"Arch Dis Child"},{"issue":"235","key":"2025101519574038000_dgaf099-B28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/adc.44.235.291","article-title":"Variations in pattern of pubertal changes in girls","volume":"44","author":"Marshall","year":"1969","journal-title":"Arch Dis Child"},{"issue":"22","key":"2025101519574038000_dgaf099-B29","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMcp0800459","article-title":"Clinical practice. Precocious puberty","volume":"358","author":"Carel","year":"2008","journal-title":"N Engl J Med"},{"key":"2025101519574038000_dgaf099-B30","unstructured":"Galderisi A . Supplemental Figures and Tables. Figshare. 2024. https:\/\/10.6084\/m9.figshare.27986939"},{"issue":"Supplement_1","key":"2025101519574038000_dgaf099-B31","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.2337\/dc24-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"8","key":"2025101519574038000_dgaf099-B32","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD clinical practice consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"issue":"2","key":"2025101519574038000_dgaf099-B33","doi-asserted-by":"crossref","first-page":"e194498","DOI":"10.1001\/jamapediatrics.2019.4498","article-title":"Prevalence of prediabetes among adolescents and young adults in the United States, 2005\u20132016","volume":"174","author":"Andes","year":"2020","journal-title":"JAMA Pediatr"},{"issue":"10","key":"2025101519574038000_dgaf099-B34","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S2352-4642(18)30235-9","article-title":"Trajectories of changes in glucose tolerance in a multiethnic cohort of obese youths: an observational prospective analysis","volume":"2","author":"Galderisi","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"issue":"3","key":"2025101519574038000_dgaf099-B35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S2352-4642(17)30044-5","article-title":"Prediabetes in youth\u2014mechanisms and biomarkers","volume":"1","author":"Weiss","year":"2017","journal-title":"Lancet Child Adolesc Health"},{"issue":"5","key":"2025101519574038000_dgaf099-B36","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/dom.13640","article-title":"The one-hour post-load plasma glucose predicts progression to prediabetes in a multiethnic cohort of obese youths","volume":"21","author":"Trico","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2025101519574038000_dgaf099-B37","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2337\/diacare.28.4.902","article-title":"Predictors of changes in glucose tolerance status in obese youth","volume":"28","author":"Weiss","year":"2005","journal-title":"Diabetes Care"},{"issue":"1","key":"2025101519574038000_dgaf099-B38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2337\/diabetes.54.1.166","article-title":"Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes","volume":"54","author":"Lyssenko","year":"2005","journal-title":"Diabetes"},{"issue":"9","key":"2025101519574038000_dgaf099-B39","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2337\/dc09-0523","article-title":"Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program","volume":"32","author":"Perreault","year":"2009","journal-title":"Diabetes Care"},{"issue":"1","key":"2025101519574038000_dgaf099-B40","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000530571","article-title":"Improvements in glucose regulation in children and young people with cystic fibrosis-related diabetes following initiation of elexacaftor\/tezacaftor\/ivacaftor","volume":"97","author":"Park","year":"2024","journal-title":"Horm Res Paediatr"},{"issue":"3","key":"2025101519574038000_dgaf099-B41","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jcf.2015.10.012","article-title":"CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation","volume":"15","author":"Tsabari","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"2","key":"2025101519574038000_dgaf099-B42","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcf.2017.11.016","article-title":"Effect of lumacaftor\/ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients","volume":"17","author":"Thomassen","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"1","key":"2025101519574038000_dgaf099-B43","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcf.2018.07.010","article-title":"Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor","volume":"18","author":"Li","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"2","key":"2025101519574038000_dgaf099-B44","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jcf.2020.09.001","article-title":"Lumacaftor\/ivacaftor therapy fails to increase insulin secretion in F508del\/F508del CF patients","volume":"20","author":"Moheet","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"10","key":"2025101519574038000_dgaf099-B45","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s40618-021-01525-4","article-title":"Lumacaftor\/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion","volume":"44","author":"Colombo","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2025101519574038000_dgaf099-B46","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0022-3476(89)80438-X","article-title":"Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity","volume":"114","author":"Caprio","year":"1989","journal-title":"J Pediatr"},{"issue":"6 Pt 1","key":"2025101519574038000_dgaf099-B47","first-page":"E885","article-title":"Effects of puberty and diabetes on metabolism of insulin-sensitive fuels","volume":"266","author":"Caprio","year":"1994","journal-title":"Am J Physiol"},{"key":"2025101519574038000_dgaf099-B48","first-page":"100311","article-title":"Glycemia and beta-cell function before and after elexacaftor\/tezacaftor\/ivacaftor in youth and adults with cystic fibrosis","volume":"30","author":"Chan","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"2025101519574038000_dgaf099-B49","doi-asserted-by":"crossref","first-page":"852551","DOI":"10.3389\/fped.2022.852551","article-title":"Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis-an observational pilot study","volume":"10","author":"Korten","year":"2022","journal-title":"Front Pediatr"},{"issue":"5","key":"2025101519574038000_dgaf099-B50","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025101519574038000_dgaf099-B51","author":"Cystic Fibrosis Foundation - NACFC","year":"2024"},{"issue":"14","key":"2025101519574038000_dgaf099-B52","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.3390\/jcm11144149","article-title":"Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis","volume":"11","author":"Piona","year":"2022","journal-title":"J Clin Med"},{"issue":"9","key":"2025101519574038000_dgaf099-B53","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"issue":"7","key":"2025101519574038000_dgaf099-B54","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1399-5448.2009.00632.x","article-title":"Oral glucose tolerance testing in children with cystic fibrosis","volume":"11","author":"Ode","year":"2010","journal-title":"Pediatr Diabetes"},{"key":"2025101519574038000_dgaf099-B55","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-18-0468","article-title":"Survival in a bad neighborhood: pancreatic islets in cystic fibrosis","author":"Norris","year":"2019","journal-title":"J Endocrinol"},{"issue":"9","key":"2025101519574038000_dgaf099-B56","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.3390\/ijms21093133","article-title":"What role does CFTR play in development, differentiation, regeneration and cancer?","volume":"21","author":"Amaral","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2025101519574038000_dgaf099-B57","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1038\/ncomms5420","article-title":"Glucose-induced electrical activities and insulin secretion in pancreatic islet beta-cells are modulated by CFTR","volume":"5","author":"Guo","year":"2014","journal-title":"Nat Commun"},{"issue":"2","key":"2025101519574038000_dgaf099-B58","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2337\/dc21-0944","article-title":"Index60 identifies individuals at appreciable risk for stage 3 among an autoantibody-positive population with normal 2-hour glucose levels: implications for current staging criteria of type 1 diabetes","volume":"45","author":"Nathan","year":"2022","journal-title":"Diabetes Care"},{"issue":"3","key":"2025101519574038000_dgaf099-B59","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00125-019-05047-w","article-title":"The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening","volume":"63","author":"Jacobsen","year":"2020","journal-title":"Diabetologia"},{"issue":"1","key":"2025101519574038000_dgaf099-B60","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1210\/clinem\/dgad472","article-title":"OGTT metrics surpass continuous glucose monitoring data for T1D prediction in multiple-autoantibody-positive individuals","volume":"109","author":"Ylescupidez","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025101519574038000_dgaf099-B61","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc10-1604","article-title":"Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis","volume":"34","author":"Brodsky","year":"2011","journal-title":"Diabetes Care"},{"issue":"1","key":"2025101519574038000_dgaf099-B62","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jcf.2015.03.001","article-title":"Characterization of patients with cystic fibrosis presenting an indeterminate glucose tolerance (INDET)","volume":"15","author":"Coriati","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"2","key":"2025101519574038000_dgaf099-B63","doi-asserted-by":"crossref","first-page":"e20210307","DOI":"10.36416\/1806-3756\/e20210307","article-title":"Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome?","volume":"48","author":"Zorron","year":"2022","journal-title":"J Bras Pneumol"},{"issue":"6","key":"2025101519574038000_dgaf099-B64","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jcf.2016.04.004","article-title":"Variation of glucose tolerance in adult patients with cystic fibrosis: what is the potential contribution of insulin sensitivity?","volume":"15","author":"Boudreau","year":"2016","journal-title":"J Cyst Fibros"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf099\/62013621\/dgaf099.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/11\/3220\/62013621\/dgaf099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/11\/3220\/62013621\/dgaf099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T23:57:56Z","timestamp":1760572676000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/11\/3220\/8026604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":64,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,2,20]]},"published-print":{"date-parts":[[2025,10,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf099","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,2,20]]}}}